Trial · NCT03555149
Results by group247
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 247
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Regorafenib (Control) | Responders (CR + PR) | 0 | 95% Confidence Interval 0 to 17.65 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Imprime PGG + Bevacizumab | Responders (CR + PR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Isatuximab | Responders (CR + PR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Selicrelumab + Bevacizumab | Responders (CR + PR) | 0 | 95% Confidence Interval 0 to 45.93 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Idasanutlin | Responders (CR + PR) | 0 | 95% Confidence Interval 0 to 60.24 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Regorafenib | Responders (CR + PR) | 6.7 | 95% Confidence Interval 0.17 to 31.95 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Regorafenib + AB928 | Responders (CR + PR) | 6.7 | 95% Confidence Interval 0.17 to 31.95 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + LOAd703 | Responders (CR + PR) | 0 | 95% Confidence Interval 0 to 84.19 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Regorafenib (Control) | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 17.65 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Imprime PGG + Bevacizumab | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Isatuximab | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Selicrelumab + Bevacizumab | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 45.93 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Idasanutlin | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 60.24 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Regorafenib | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Regorafenib + AB928 | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + LOAd703 | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 84.19 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Regorafenib (Control) | Partial Response (PR) | 0 | 95% Confidence Interval 0 to 17.65 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Imprime PGG + Bevacizumab | Partial Response (PR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Isatuximab | Partial Response (PR) | 0 | 95% Confidence Interval 0 to 21.80 | Percentage of Participants |
| Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Atezolizumab + Selicrelumab + Bevacizumab | Partial Response (PR) | 0 | 95% Confidence Interval 0 to 45.93 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03555149/results